Back to top
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Image: Bigstock
Aurinia Pharmaceuticals (AUPH) Looks Good: Stock Adds 7.8% in Session
Aurinia Pharmaceuticals Inc. (AUPH - Free Report) was a big mover last session, as the company saw its shares rise nearly 8% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $6.10–$7.09 in the past one-month time frame, witnessed a sharp increase yesterday.
The company has seen no estimate revisions in the past one month, while its Zacks Consensus Estimate for the current quarter has moved lower over the same time frame, suggesting there may be trouble down the road. So make sure to keep an eye on this stock going forward, to see if this recent move higher can last.
Aurinia Pharmaceuticals currently has a Zacks Rank #1 (Strong Buy) while its Earnings ESP is negative.
Aurinia Pharmaceuticals Inc Price and Consensus
Aurinia Pharmaceuticals Inc Price and Consensus | Aurinia Pharmaceuticals Inc Quote
Another stock that warrants a look in the Medical - Drugs industry is MEI Pharma, Inc.(MEIP - Free Report) which also carries a Zacks Rank #1. You can see the complete list of today’s Zacks #1 Rank stocks here.
Is AUPH going up? Or down? Predict to see what others think: Up or Down
5 Trades Could Profit ""Big-League"" from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure.
See these buy recommendations now >>